Grünenthal is a global leader in pain management and related diseases, committed to changing lives for the better through innovative treatments and state-of-the-art technologies. Established in 1946 and headquartered in Aachen, Germany, Grünenthal operates as a fully integrated pharmaceutical company. With a strong focus on delivering excellence in drug development and manufacturing, the company serves a wide range of markets and is present in approximately 100 countries. In 2022, Grünenthal employed around 4,400 people and achieved revenues of €1.7 billion.

Services include:
– Small Molecule

– Drug Substance Manufacturing (API)

– Drug Product Formulation (FDF)

– Packaging

– Nasal drug delivery Contract Manufacturing Organisation (CMO)

Grünenthal continues to uphold its dedication to innovation in pharmaceutical manufacturing and service provision within the healthcare industry.